MediciNova announced that an abstract regarding a clinical trial of MN-166 in the treatment of Amyotrophic Lateral Sclerosis, COMBAT-ALS study has been selected for a poster presentation at the 35th International Symposium on ALS / MND to be held December 6-8, 2024 in Montreal, Canada. The poster presentation will be presented by lead Principal Investigator of this clinical trial, Bjorn Oskarsson, MD, FAAN Associate Professor of Neurology at Jacksonville, FL, Director of ALS, Center of Excellence.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNOV:
- MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition